Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial

Pediatric Blood & Cancer
Vineeta GuptaTej Bali Singh

Abstract

Several measures including drugs have been tried to reduce anthracycline cardiotoxicity. The lack of randomized trials prompted this study to assess the role of an angiotensin converting enzyme (ACE) inhibitor (enalapril) in anthracycline-induced cardiotoxicity in children with hematological malignancies. A randomized, double-blind, placebo-controlled trial was conducted on 84 patients with leukemia (41) and lymphoma (43) who received anthracyclines (doxorubicin and/or daunorubicin) at cumulative dose ≥200 mg/m2 . The patients were randomized to receive either enalapril [group A (n = 44)] or placebo [group B (n = 40)] for 6 months. Left ventricular ejection fraction (LVEF) and cardiac biomarkers (cardiac troponin I [cTnI], probrain natriuretic peptide [proBNP], and creatine kinase MB [CK-MB]) were assessed at baseline and 6 months. The primary outcome was a measured decrease in LVEF (≥20%). Secondary outcome measures were changes in cardiac biomarkers and the development of heart failure or arrhythmias. LVEF decreased in both groups at 6 months, more so in group B (62.25 ± 5.49 vs 56.15 ± 4.79, P < 0.001). A ≥20% decrease was seen in 3 patients in group B but none in group A (P = 0.21). Cardiac biomarkers increased more in grou...Continue Reading

References

Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Jun 20, 2006·Seminars in Oncology·Perry Elliott
Aug 1, 2008·Expert Review of Cardiovascular Therapy·Brent Anderson, Douglas B Sawyer
Apr 4, 2009·The Lancet Oncology·Renske AltenaJourik A Gietema
Aug 9, 2012·Future Cardiology·Danielle HarakeSteven E Lipshultz
Oct 13, 2012·Journal of Experimental & Clinical Cancer Research : CR·Beata MladosievicovaIveta Simkova
Sep 18, 2014·Acta Haematologica·Steven E LipshultzTracie L Miller
Dec 2, 2014·Pediatric Clinics of North America·Wendy LandierSmita Bhatia
Dec 3, 2014·Clinical Biochemistry·Eric S ChristensonBen H Park
Apr 15, 2015·Indian Journal of Pediatrics·Swapnil Gadhave, Aarti Nagarkar
Jun 1, 2015·Current Cardiology Reports·Patrick L Stevens, Daniel J Lenihan
Feb 27, 2016·CA: a Cancer Journal for Clinicians·Giuseppe CuriglianoCarlo Maria Cipolla
Mar 24, 2016·Cardiovascular Toxicology·Ghasem JanbabaiJamshid Yazdani

❮ Previous
Next ❯

Citations

Jun 17, 2020·Frontiers in Pharmacology·Yili ZhangYong Wang
Apr 24, 2020·Frontiers in Cardiovascular Medicine·Verena SchwachRobert Passier
Mar 11, 2020·Cardio-Oncology·Neha BansalSteven E Lipshultz
Sep 12, 2020·The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology·Ahmed Ayuna, Nik Abidin
Jan 7, 2021·Heart Failure Reviews·Diana GonciarLucia Agoston-Coldea
May 15, 2021·Journal of Adolescent and Young Adult Oncology·Yutthapong Temtanakitpaisan, Suchaorn Saengnipanthkul
Aug 13, 2021·Bone Marrow Transplantation·Akihiro Ohmoto, Shigeo Fuji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.